SPECIAL EDITION
COVID-19: A GLOBAL PROBLEM FOR MODERN CIVILIZATION
PROSPECTS FOR APPLICATION OF «AZEOMED» MINERAL COMPLEX FOR PREVENTION AND TREATMENT OF COVID-19 AND OTHER SEVERE ILLNESS
1Prof. Dr. med. Karl Hecht, 2,3Prof. Dr. Elchin Khalilov, 4Dr. med. Ilse Triebnig, 5,6PhD.Tamila Khalilova, 7Prof. Dr. Mahbuba Veliyeva, 8Prof. Dr. Farkhanda Sadikhova, 1Dr. Yelena Savoley
1World Organization for Scientific Cooperation (Germany, Munich);
2International Academy of Science H&E, Azerbaijan Section (Azerbaijan, Baku);
3«AZERZEOLIT» Scientific Production Corporation (Azerbaijan, Baku);
4WOSCO SWB (Carinthia, Austria); [email protected]
5International Association. Zeolite: Health and Ecology (Germany, Munich);
6“Intergeo-Tethys” International Scientific and Technical Complex, (Azerbaijan, Baku);
7Department of Pharmaceutical Technology and Management
of Azerbaijan Medical University (Azerbaijan, Baku); [email protected]
8Department of Microbiology and Epidemiology
of A.Aliyev Azerbaijan State Advanced Training Institute (Azerbaijan, Baku);
SUMMARY
The paper discusses the results of 20 years of clinical and laboratory studies of the effectiveness of the mineral composition - food supplement «AZEOMED» based on natural zeolite - clinoptilolite of the Aydag deposit of Azerbaijan. The results of comprehensive studies published in scientific papers and having official conclusions of state medical institutions and scientists of Azerbaijan, Germany, Austria and Russia made it possible to establish the high effectiveness of the drug «AZEOMED» in the prevention and treatment of severe infectious diseases - bird flu H5N1, pulmonary tuberculosis, polio, HIV / AIDS, ARI and other viral and bacterial infections.
Clinical and laboratory studies have established that «AZEOMED» has highly effective immunotropic properties, is an effective detoxifier and antioxidant, and helps to eliminate toxins from the body, including those produced by pathogenic bacteria, viruses and fungi. In addition, the drug has antiviral, antibacterial and antifungal activity and adsorbs many types of viruses and bacteria. The effectiveness of the drug in the prevention and treatment of diseases of the cardiovascular system, hypertension, diabetes and and cancer has also been established.
Based on an in-depth analysis of the many years of results of clinical and laboratory studies of the drug «AZEOMED» and its biophysical, biochemical and physiological mechanisms of exposure to the human body and viral and bacterial infections, the authors consider the use of the drug «AZEOMED» for the prevention and treatment of COVID-19 to be promising. At the end of the paper, information is given on analogues of the AZEOMED mineral complex based on natural clinoptilolite-zeolite, which are produced in various countries.
Key words: COVID-19 pandemic, «AZEOMED» mineral complex, coronavirus, viral and bacterial infection, antiviral and antibacterial activity, immunostimulant, detoxicant, antioxidant.
1. COVID-19 PANDEMIC - MODERN CHALLENGES FOR
HUMANITY AND POSSIBLE WAYS TO OVERCOME THEM
by Dr. Tamila Khalilova, Azerbaijan
The COVID-19 outbreak began in mid-December 2019 in Wuhan, Central China. Until February 19, 2020, SARS-CoV-2 infected more than 75,000 people in China and 25 more countries on five continents /1/.
Coronavirus infection has been known since 1965. Currently, more than forty types of the virus have been described; there are seven examples of overcoming the interspecific barrier between the animal world and humans. The most striking examples of this overcoming are the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), first reported in China in 2002. Its subspecies is today's COVID-19. As for the current situation, the coronavirus COVID-19 behaves as a typical natural focal infection /1/.
In the framework of phytoepidemiological approaches, specific directions of virus transmission from person to person and sources for international cases of infection were identified.
The authors /1/ suggest that SARS-CoV-2 may already have been widely distributed among people in Wuhan until December 2019, probably from mid to late November. Some infected patients may have been overlooked because they had mild symptoms.
According to /2/, (as of March 28, 18:20 GTM), the number of people infected worldwide is 645.956 people, the number of deaths is 29.980 (4.6%), the number of people who have recovered 139.552 (21.7%), who were sick at the time of receiving the data 476.424 , of which moderate severity is 451.686 (95%), in critical condition 24, 738 (5%).
Figure 1: Diagram of the dynamics of patients who died and recovered in World, according to /2/.
Data for the top 10 countries by the number of patients with coronavirus are shown in Table 1. /2/.
The evolutionary history of SARS-CoV-2, studies of the distribution dynamics of COVID-19, and a complex of genomic studies are given in /1,3-7/.
We have compiled graphs showing the statistics of mortality from coronavirus depending on the age and type of chronic diseases according to the China Center for Disease Control and Prevention, Fig.2.
Figure 2: Coronavirus mortality statistics in%: 1 - depending on age; 2 - depending on chronic diseases.
(These conclusions are based on 72,314 cases studied according to the /9/).
A study by Chinese scientists /8/ based on a statistical analysis of coronavirus patients in Wuhan Pulmonary Hospital and Jinyintan Hospital in Wuhan revealed very important trends and patterns of the main risk groups for Covid-19 infection. The following is table 2 given in /8/.
Studying the data in table 2 and graphs in figure 2. we understand that one of the main tasks for scientists is the development of methods and appropriate drugs that can minimize the likelihood of a decrease in immunity and the possibility of infection with coronavirus for people with a high risk of morbidity.
The categories of high mortality from coronavirus include people with concomitant diseases of the cardiovascular system (13.2%), diabetes (9.2%), hypertension (8.4%), chronic respiratory diseases (8%) and cancer patients ( 7.6%).
By age categories, old people aged ≥80 years old (maximum risk), 70-79 years old (very high risk), 60-69 years old (high risk) are at maximum risk.
Currently, many research institutes, universities and medical institutions of the world are involved in the development of an effective vaccine against COVID-19, in which leading scientists of various fields of science participate: medicine, microbiology, virology, pharmaceuticals, genetic engineering,